latest news releases from the newsroom
CombiMatrix Will Collaborate with Clarient to Market, Sell Novel Genomics-Based Test for Chronic Lymphocytic Leukemia
MUKILTEO, Wash. and ALISO VIEJO, Calif., Jan. 31, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) and Clarient, Inc. (Nasdaq:CLRT) today jointly announced establishment of a strategic partnership to market and sell a novel genomics-based cancer test called HemeScan, a comprehensive test related to the treatment and care of chronic lymphocytic leukemia (CLL), among other cancers. The HemeScan(tm) test was developed by CombiMatrix and validated in collaboration with a team of high-profile academic centers, including the M.D. Anderson Cancer Center in Houston, the University of Texas Health Science Center in San Antonio, and Netherlands Cancer Institute in Amsterdam.
Magma Design Automation
Magma and Common Platform Technology Alliance Deliver DFM Solution for 65 nm IC Design Success
SAN JOSE, Calif., Jan. 31, 2008 (PRIME NEWSWIRE) -- Magma(r) Design Automation Inc. (Nasdaq:LAVA), a provider of chip design software, today announced the availability of a qualified design for manufacturability (DFM) flow for ICs targeted at 65-nanometer (nm) processes of Common Platform technology -- an alliance between IBM, Chartered Semiconductor Manufacturing and Samsung. The flow is based on Magma's DFM-aware design environment that accounts for process variability and lithographic effects in the context of timing, power, noise and yield. With this flow, Magma and the Common Platform technology alliance enable mutual customers to meet their performance, yield and time-to-market goals.